银屑病中的多病共存作为银屑病关节炎的风险因素:一项基于人群的研究
该回顾性队列研究基于罗切斯特流行病学项目,分析银屑病患者多病共存情况及其与银屑病关节炎(PsA)发生的关联。在1088例患病期银屑病患者中,多病共存较对照组更常见(OR 1.35和1.48),中位随访13.3年间23例发生PsA,多病共存与PsA风险升高3倍相关。
要点
- 患病期银屑病患者多病共存较对照组更常见,OR 1.35(≥2种)和1.48(≥5种)。
- 银屑病发病时多病共存与PsA风险升高3倍相关。
- 中位随访13.3年,23例(15年累积发病率2.9%)发生PsA。
核心结论
- 多病共存仅在患病期而非发病期银屑病患者中较一般人群更常见,提示银屑病患者多病共存可能加速发展。
- 银屑病发病时多病共存显著增加PsA发生风险,凸显监测多病共存银屑病患者PsA发生的重要性。
研究设计与样本
- 采用罗切斯特流行病学项目进行的回顾性队列研究。
- 以年龄、性别和县1:1匹配无银屑病个体作为对照组。
- 多病共存定义为既往5年内相隔≥30天的两个及以上临床分类软件编码。
- PsA采用银屑病关节炎分类标准(CASPAR)定义。
主要发现
- 817例新发银屑病患者平均年龄45.2岁,女性占52.0%,82.0%为中重度银屑病,与对照组多病共存无差异。
- 1088例患病期银屑病患者中多病共存较1086例对照组显著更常见,≥2种和≥5种多病共存的比值比分别为1.35和1.48。
- 中位随访13.3年,23例发生PsA,15年累积发病率为2.9%。
- 多病共存(≥2种)与PsA风险升高3倍相关。
临床怎么用
- 作者认为,应监测多病共存的银屑病患者以发现PsA的发生。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To examine multimorbidity in psoriasis and its association with the development of psoriatic arthritis (PsA). METHODS: A retrospective cohort study was performed using the Rochester Epidemiology Project. Population-based incidence (2000-09) and prevalence (1 January 2010) cohorts of psoriasis were identified by manual chart review. A cohort of individuals without psoriasis (comparators) were identified (1:1 matched on age, sex and county). Morbidities were defined using two or more Clinical Classification Software codes ≥30 days apart within prior 5 years. PsA was defined using ClASsification of Psoriatic ARthritis (CASPAR) criteria. χ2 and rank-sum tests were used to compare morbidities, and age-, sex- and race-adjusted Cox models to examine the association of baseline morbidities in psoriasis with development of PsA. RESULTS: Among 817 incident psoriasis patients, the mean age was 45.2 years with 52.0% females, and 82.0% moderate/severe psoriasis. No multimorbidity differences were found between incident psoriasis patients and comparators. However, in the 1088 prevalent psoriasis patients, multimorbidity was significantly more common compared with 1086 comparators (odds ratio 1.35 and 1.48 for two or more and five or more morbidities, respectively). Over a median 13.3-year follow-up, 23 patients (cumulative incidence: 2.9% by 15 years) developed PsA. Multimorbidity (two or more morbidities) was associated with a 3-fold higher risk of developing PsA. CONCLUSION: Multimorbidity was more common in the prevalent but not incident cohort of psoriasis compared with the general population, suggesting that patients with psoriasis may experience accelerated development of multimorbidity. Moreover, multimorbidity at psoriasis onset significantly increased the risk of developing PsA, highlighting the importance of monitoring multimorbid psoriasis patients for the development of PsA.
引用
- Karmacharya P, Chakradhar R, Hulshizer CA, et al. Multimorbidity in psoriasis as a risk factor for psoriatic arthritis: a population-based study. Rheumatology (Oxford). 2025. PMID: 38291896. doi:10.1093/rheumatology/keae040
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。